Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer

BackgroundCurrently, the prognosis for metastatic colorectal cancer (mCRC) remains unfavorable. However, as advancements in local and systemic treatment modalities progress, therapeutic strategies for mCRC are becoming increasingly varied. For patients presenting with a limited number of metastases,...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Wei Qian, Huatang Zhang, Yanhua Mo, Chaoyang Wu, Juntong Liu, Yuyi Pen, Cantu Fang, Jincheng Meng
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2026-02-01
Цуврал:	Frontiers in Oncology
Нөхцлүүд:	fruquintinib immunotherapy metastatic colorectal cancer microwave ablation tislelizumab
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1728876/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!